MQMichael Qiu

Michael Qiu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Michael Qiu has a total of 34 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Nudging Health Care Providers’ Adoption of Clinical Decision Support: Protocol for the User-Centered Development of a Behavioral Economics–Inspired Electronic Health Record Tool

    by Safiya Richardson, Katherine Dauber-Decker, Jeffrey Solomon, Sundas Khan, Douglas Barnaby, John Chelico, Michael Qiu, Yan Liu, Devin Mann, Renee Pekmezaris, et al.

    Background: The improvements in care resulting from clinical decision support (CDS) have been significantly limited by consistently low health care provider adoption. Health care provider attitudes toward CDS, specifically psychological and behavioral barriers, are not typically addressed during any stage of CDS development, although they represent an important barrier to adoption. Emerging evidence has shown the surprising power of using insights from the field of behavioral economics to address psychological and behavioral barriers. Nudges are formal applications of behavioral economics, defined as positive reinforcement and indirect suggestions that have a nonforced effect on decision-making. Objective: Our goal is to employ a user-centered design process to develop a CDS tool—the pulmonary embolism (PE) risk calculator—for PE risk stratification in the emergency department that incorporates a behavior theory–informed nudge to address identified behavioral barriers to use. Methods: All study activities took place at a large academic health system in the New York City metropolitan area. Our study used a user-centered and behavior theory–based approach to achieve the following two aims: (1) use mixed methods to identify health care provider barriers to the use of an active CDS tool for PE risk stratification and (2) develop a new CDS tool—the PE risk calculator—that addresses behavioral barriers to health care providers’ adoption of CDS by incorporating nudges into the user interface. These aims were guided by the revised Observational Research Behavioral Information Technology model. A total of 50 clinicians who used the original version of the tool were surveyed with a quantitative instrument that we developed based on a behavior theory framework—the Capability-Opportunity-Motivation-Behavior framework. A semistructured interview guide was developed based on the survey responses. Inductive methods were used to analyze interview session notes and audio recordings from 12 interviews. Revised versions of the tool were developed that incorporated nudges. Results: Functional prototypes were developed by using Axure PRO (Axure Software Solutions) software and usability tested with end users in an iterative agile process (n=10). The tool was redesigned to address 4 identified major barriers to tool use; we included 2 nudges and a default. The 6-month pilot trial for the tool was launched on October 1, 2021. Conclusions: Clinicians highlighted several important psychological and behavioral barriers to CDS use. Addressing these barriers, along with conducting traditional usability testing, facilitated the development of a tool with greater potential to transform clinical care. The tool will be tested in a prospective pilot trial. International Registered Report Identifier (IRRID): DERR1-10.2196/42653


  • Open Access

    Post-COVID-19 Infection With Meticillin-Sensitive Staphylococcus aureus (MSSA) Bacteremia, Discitis/Osteomyelitis, and Diffuse Abscesses: A Case Report

    by Michael Qiu, Deepthi Jayasekara, Arindra Jayasekara

    Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2), has been associated with a plethora of symptoms weeks after the acute infection. While many reports have investigated the novel syndrome of post-acute sequelae of COVID-19, fewer studies have examined post-COVID-19 secondary infections, which may be distinct from typical post-viral bacterial infections due to the multiorgan involvement of COVID-19. This case report aims to highlight a presentation in which a 65-year-old man had COVID-19 and subsequently developed methicillin-sensitive Staphylococcus aureus (MSSA) bacteremia with widespread seeding of secondary infections, including abscesses in the hand and paravertebral regions as well as discitis/osteomyelitis of the cervical spine. Further studies are needed to investigate whether an increased susceptibility to unusual secondary bacterial infections is present in post-COVID-19 patients.


  • Quality-of-Care Implications of Antimicrobial Prescription Patterns for Acute Respiratory Tract Infections

    by Vansha Singh, Liron Sinvani, Bruce Hirsch, Kayla Finuf, Claire Popplewell, Michael Qiu, Michele Pisano, Nina Kohn, Renee Pekmezaris, Gisele Wolf-Klein

    The Centers for Disease Control and Prevention estimates that half of the antibiotic prescriptions for acute respiratory tract infections (ARTIs) in ambulatory care settings are unnecessary. To better understand the quality-of-care implications of prescription patterns for ARTIs, we conducted a retrospective chart review of outpatient ARTI visits, across a large integrated health system, and examined the association of patient characteristics with receiving antimicrobials, as well as the association between receiving antimicrobials and healthcare utilization (outpatient and emergency department visits). We found that 55.4% of all ARTI outpatients were treated with antimicrobials. There was no association between patient demographics and antimicrobial prescriptions on either the first (p < .0771) or follow-up (p < .6316) visits. A lower comorbidity score was significantly associated with receiving antimicrobials (p < .0022). Patients who received antimicrobials at the first visit had significantly higher number of follow-up visits (p < .005) and more follow-up antimicrobial prescriptions (p < .0066) as compared with patients who did not receive antimicrobials at the first visit. Our results highlight the potential for clinicians to improve quality of care in ARTI management.


  • Safely Administering Potential QTc Prolonging Therapy Across a Large Health Care System in the COVID-19 Era

    by Moussa Saleh, James Gabriels, David Chang, Joanna Fishbein, Michael Qiu, Stavros E. Mountantonakis, Laurence M. Epstein, on behalf of the Northwell COVID-19 Research Consortium

    Background: The severe acute respiratory syndrome coronavirus 2 (SARs-CoV-2) has resulted in a global pandemic. Hydroxychloroquine±azithromycin have been widely used to treat coronavirus disease 2019 (COVID-19) despite a paucity of evidence regarding efficacy. The incidence of torsade de pointes remains unknown. Widespread use of these medications forced overwhelmed health care systems to search for ways to effectively monitor these patients while simultaneously trying to minimize health care provider exposure and use of personal protective equipment. Methods: Patients with COVID-19 positive who received hydroxychloroquine±azithromycin across 13 hospitals between March 1 and April 15 were included in this study. A comprehensive search of the electronic medical records was performed using a proprietary python script to identify any mention of QT prolongation, ventricular tachy-arrhythmias and cardiac arrest. Results: The primary outcome of torsade de pointes was observed in 1 (0.015%) out of 6476 hospitalized patients with COVID-19 receiving hydroxychloroquine±azithromycin. Sixty-seven (1.03%) had hydroxychloroquine±azithromycin held or discontinued due to an average QT prolongation of 60.5±40.5 ms from a baseline QTc of 473.7±35.9 ms to a peak QTc of 532.6±31.6 ms. Of these patients, hydroxychloroquine±azithromycin were discontinued in 58 patients (86.6%), while one or more doses of therapy were held in the remaining nine (13.4%). A simplified approach to monitoring for QT prolongation and arrythmia was implemented on April 5. There were no deaths related to the medications with the simplified monitoring approach and health care provider exposure was reduced. Conclusions: The risk of torsade de pointes is low in hospitalized patients with COVID-19 receiving hydroxychloroquine±azithromycin therapy.


  • External validation of the COMPASS-Cancer Associated Thrombosis Study: A predictive score to identify patients with solid tumors on treatment who are at risk for venous thromboembolism.

    by Lalitha N Anand, Alex C Spyropoulos, Joanna B Eldredge, Soheila Nourabadi, Meng Zhang, Michael Qiu, David Rosenberg

    E18005 Background: A predictive model to identify patients on active treatment for solid tumors at risk for venous thromboembolism (VTE) remains an important clinical need. The COMPASS-CAT Risk Assessment Model (RAM) for VTE in a Eurasian patient population with solid tumors undergoing active treatment displayed good discrimination to identify patients into low/intermediate versus high VTE risk groups. We sought to externally validate this RAM in a North American cancer population. Methods: Patients age > 17 years who presented to the Monter Cancer Center between 1/12014 to 12/31/2016 with breast, ovarian, lung, or colorectal cancers were included. The COMPASS CAT RAM included 8 scored variables that were identified by ICD-9 and -10 codes and chart review. The primary endpoint at 6-month study follow-up was symptomatic VTE. Area under the ROC Curve (AUC) was calculated. We calculated a binary cut off to define VTE risk groups into low/intermediate and high VTE risk categories and calculated sensitivity, specificity, and negative and positive predictive values (NPV, PPV). Results: 3814 patients were included with a mean age of 64, of whom 49%, 5%, 29%, and 17% had breast, ovarian, lung, and colorectal cancer, and 52% had localized and 48% had advanced stage disease. In 94% of patients, cancer was diagnosed within the last 6 months prior to inclusion and 46% of patients were on active therapy when evaluated. Symptomatic VTE at 6-month follow-up occurred in 5.85% of patients. The AUC was 0.62. Using model cut-offs of 0-6 or > 7 points, patients stratified into low/intermediate and high-risk groups had VTE rates of 2.27% and 6.31%, respectively. The sensitivity, specificity, NPV, and PPV of the RAM were 95%,12%, 97.73%, and 6.31%, respectively. Conclusions: In this large retrospective external validation study of the COMPASS-CAT RAM for VTE in cancer patients undergoing active treatment, model discrimination and calibration was fair. Further prospective validation studies are needed before the model can be implemented into routine clinical practice for primary thromboprophylaxis of high VTE risk cancer patients with solid tumors.